Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
March 25 2024 - 4:30PM
Zevra Therapeutics, Inc. (NasdaqGS:
ZVRA) (Zevra or the Company), a rare disease
therapeutics company, today announced that it will participate
in the upcoming 23rd Annual Needham Virtual Healthcare Conference
being held virtually on April 8-9, 2024. The Company’s presentation
will take place on Monday, April 8, 2024, at 3:45 p.m. ET.
Additionally, members of Zevra’s management team will be available
for one-on-one investor meetings with registered attendees
throughout the conference.
The live webcast will be available here.
Following Zevra’s presentation, the archived presentation will be
accessible under “Events & Presentations” on the Investor
Relations section of Zevra’s website at investors.zevra.com. To
register for the conference, contact your Needham Sales
Representative.
About Zevra Therapeutics:
Zevra Therapeutics is a rare disease company
combining science, data, and patient needs to create
transformational therapies for diseases with limited or no
treatment options. Our mission is to bring life-changing
therapeutics to people living with rare diseases. With unique,
data-driven development and commercialization strategies, the
Company is overcoming complex drug development challenges to make
new therapies available to the rare disease community.
For more information, please visit www.zevra.com
or follow us on X (formerly Twitter)
and LinkedIn.
Cautionary Note Concerning Forward-Looking
Statements:
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements include all
statements that do not relate solely to historical or current
facts, including without limitation statements regarding upcoming
events or Zevra’s participation at such events. Forward-looking
statements are based on information currently available to Zevra
and its current plans or expectations. They are subject to several
known and unknown uncertainties, risks, and other important factors
that may cause our actual results, performance, or achievements to
be materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. These and other important factors are described in
detail in the "Risk Factors" section of Zevra’s Annual Report on
Form 10-K for the year ended December 31, 2022, as updated in
Zevra’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2023, and Zevra’s other filings with the Securities
and Exchange Commission. While we may elect to update such
forward-looking statements at some point in the future, except as
required by law, we disclaim any obligation to do so, even if
subsequent events cause our views to change. Although we believe
the expectations reflected in such forward-looking statements are
reasonable, we cannot assure that such expectations will prove
correct. These forward-looking statements should not be relied upon
as representing our views as of any date after the date of this
press release.
Zevra Contacts:
Nichol Ochsner +1 (732)
754-2545 nochsner@zevra.com
Russo Partners Contacts:
David Schull +1 (858)
717-2310 david.schull@russopartnersllc.com
Ignacio Guerrero-Ros, Ph.D. +1 (646)
942-5604 ignacio.guerrero-ros@russopartnersllc.com
Zevra Therapeutics (NASDAQ:ZVRA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Zevra Therapeutics (NASDAQ:ZVRA)
Historical Stock Chart
From Oct 2023 to Oct 2024